P. Reaper

发表

A DNA damage checkpoint response in telomere-initiated senescence

N. Carter, H. Fiegler, S. Jackson, 2003, Nature.

Development of pharmacodynamic biomarkers for ATR inhibitors

N. Curtin, P. Reaper, Tao Chen, 2015, Molecular oncology.

Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970

P. Reaper, P. Charlton, J. Pollard, 2014, Oncotarget.

Activation of the DNA Damage Response by Telomere Attrition: A Passage to Cellular Senescence

S. Jackson, F. D. D. Fagagna, P. Reaper, 2004, Cell cycle.

The ATR-p53 pathway is suppressed in noncycling normal and malignant lymphocytes

A. Pettitt, P. Sherrington, P. Reaper, 2004, Oncogene.

Identification and Characterization of a Novel and Specific Inhibitor of the Ataxia-Telangiectasia Mutated Kinase ATM

N. Curtin, S. Jackson, P. Reaper, 2004, Cancer Research.

Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents.

P. Reaper, J. Pollard, M. Mortimore, 2011, Journal of medicinal chemistry.

Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation

B. Cornelissen, R. Muschel, E. Fokas, 2012, Cell Death and Disease.

ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A

Samuel E. Jones, A. Ashworth, Colm J. Ryan, 2016, Nature Communications.

Rational Design of 5-(4-(Isopropylsulfonyl)phenyl)-3-(3-(4-((methylamino)methyl)phenyl)isoxazol-5-yl)pyrazin-2-amine (VX-970, M6620): Optimization of Intra- and Intermolecular Polar Interactions of a New Ataxia Telangiectasia Mutated and Rad3-Related (ATR) Kinase Inhibitor.

P. Reaper, J. Golec, M. Griffiths, 2019, Journal of medicinal chemistry.

ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses.

Y. Pommier, R. Guha, Joel Morris, 2014, Cancer research.

Targeting radiation-resistant hypoxic tumour cells through ATR inhibition

W. Mckenna, E. Hammond, I. Pires, 2012, British Journal of Cancer.

Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR.

P. Reaper, P. Charlton, J. Pollard, 2011, Nature chemical biology.

Rapid PIKK-Dependent Release of Chk1 from Chromatin Promotes the DNA-Damage Checkpoint Response

S. Jackson, V. Smits, P. Reaper, 2006, Current Biology.

Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase Activities

T. Helleday, R. Kuiper, P. Reaper, 2015, Cell reports.

Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase Activities

T. Helleday, R. Kuiper, P. Reaper, 2015, Cell reports.

The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy

R. Muschel, E. Fokas, W. Mckenna, 2012, Cancer biology & therapy.

Structure of human Bloom's syndrome helicase in complex with ADP and duplex DNA.

P. Reaper, P. Charlton, Valérie Legris, 2014, Acta crystallographica. Section D, Biological crystallography.

Abstract 369: Antitumor activity of M4344, a potent and selective ATR inhibitor, in monotherapy and combination therapy

B. Elenbaas, P. Reaper, S. Bagrodia, 2019, Experimental and Molecular Therapeutics.

Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970

P. Reaper, P. Charlton, D. Newsome, 2014, Oncotarget.